<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	
	xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>Stevens Johnson Syndrome &#187; Tibotec</title>
	<atom:link href="http://www.sjs-legal.com/tag/tibotec/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.sjs-legal.com</link>
	<description></description>
	<lastBuildDate>Wed, 28 Jul 2010 20:36:18 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>HIV treatment linked to slight risk of SJS/TEN</title>
		<link>http://www.sjs-legal.com/news/2009/02/10/hiv-treatment-linked-to-slight-risk-of-sjsten/</link>
		<comments>http://www.sjs-legal.com/news/2009/02/10/hiv-treatment-linked-to-slight-risk-of-sjsten/#comments</comments>
		<pubDate>Tue, 10 Feb 2009 14:00:45 +0000</pubDate>
		<dc:creator>Jennifer Walker-Journey</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[anti-HIV medications]]></category>
		<category><![CDATA[anti-seizure medication]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[erythema multiforme]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Hays Pharma]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV treatment]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[ibuprofen]]></category>
		<category><![CDATA[Intelence]]></category>
		<category><![CDATA[rashes]]></category>
		<category><![CDATA[SJS]]></category>
		<category><![CDATA[Stevens Johnson Syndrome]]></category>
		<category><![CDATA[TENS]]></category>
		<category><![CDATA[Tibotec]]></category>
		<category><![CDATA[toxic epidermal necrolysis]]></category>

		<guid isPermaLink="false">http://www.sjs-legal.com/?p=402</guid>
		<description><![CDATA[Drug maker Tibotec, which specializes in innovative therapeutic and diagnostic solutions for infectious diseases such as HIV/AIDS, is seeking approval from the FDA for its latest HIV treatment, Intelence, based on data from its phase-three studies of the drug when used in combination with other antiretroviral agents, according to a press release from Hays Pharma, [...]<p>SOURCE: <a href="http://www.sjs-legal.com">Stevens Johnson Syndrome</a> &rsaquo; <a href="http://www.sjs-legal.com/news/2009/02/10/hiv-treatment-linked-to-slight-risk-of-sjsten/">HIV treatment linked to slight risk of SJS/TEN</a></p>
]]></description>
			<content:encoded><![CDATA[<p><img class="alignleft size-thumbnail wp-image-411" title="intelence_bottle_lr1" src="http://www.sjs-legal.com/media/2009/02/intelence_bottle_lr1-109x150.jpg" alt="intelence bottle lr1 109x150" width="109" height="150" />Drug maker <strong>Tibotec</strong>, which specializes in innovative therapeutic and diagnostic solutions for infectious diseases such as <strong>HIV/AIDS</strong>, is seeking approval from the <strong>FDA</strong> for its latest <strong>HIV treatment</strong>, <strong>Intelence</strong>, based on data from its phase-three studies of the drug when used in combination with other antiretroviral agents, according to a press release from <a href="http://www.hayspharma.com/news/no-category/tibotec-seeks-fda-approval-for-hiv-drug/19012728">Hays Pharma</a>, a global pharmaceutical and biotech staffing and recruitment business.<span id="more-402"></span></p>
<p><strong>Intelence</strong> is a tablet available only by prescription. It is a type of anti-<strong>HIV</strong> medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI), also known as a non-nuke. It is used to control <strong>HIV</strong> infection in adults and must be used in conjunction with other <strong>HIV</strong> medications. <strong>Intelence</strong> is for patients who have previously received treatment for <strong>HIV</strong>-1 and showed resistance to NNRTIs and protease inhibitors.</p>
<p>The clinical trials revealed that <strong>Intelence</strong> does carry a slight risk for serious skin reactions such as <a href="http://www.sjs-legal.com"><strong><a href="http://www.sjs-legal.com/" title="" rel="external">Stevens Johnson Syndrome</a> (SJS),</strong></a> hypersensitivity reaction and erythema multiforme.</p>
<p>More than 200 medications have been linked to <strong><a href="http://www.sjs-legal.com/tag/sjs/" class="st_tag internal_tag" rel="tag" title="Posts tagged with SJS">SJS</a></strong> and its more severe form, <strong><a href="http://www.sjs-legal.com/toxic-epidermal-necrolysis-syndrome/" title="" rel="external">toxic epidermal necrolysis</a> (TEN)</strong>, most commonly ibuprofen, <a href="http://www.sjs-legal.com/tag/antibiotics/" class="st_tag internal_tag" rel="tag" title="Posts tagged with antibiotics">antibiotics</a> and anti-seizure medications. <strong><a href="http://www.sjs-legal.com/tag/sjs/" class="st_tag internal_tag" rel="tag" title="Posts tagged with SJS">SJS</a></strong> and TEN are severe expressions of a simple rash known as <strong>erythema multiforme</strong>. As the condition worsens, the rashes blister over causing the skin to peel off. Mucus membranes, such as the mouth and eyes, can blister over causing dehydration, infection, blindness and even death.</p>
<p>Patients taking medication, including Intelence, should be aware of the potential life-threatening risk of <strong><a href="http://www.sjs-legal.com/tag/sjs/" class="st_tag internal_tag" rel="tag" title="Posts tagged with SJS">SJS</a>/TEN </strong></p>
<p>SOURCE: <a href="http://www.sjs-legal.com">Stevens Johnson Syndrome</a> &rsaquo; <a href="http://www.sjs-legal.com/news/2009/02/10/hiv-treatment-linked-to-slight-risk-of-sjsten/">HIV treatment linked to slight risk of SJS/TEN</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.sjs-legal.com/news/2009/02/10/hiv-treatment-linked-to-slight-risk-of-sjsten/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:thumbnail url="http://www.sjs-legal.com/media/2009/02/intelence_bottle_lr1-109x150.jpg" />
		<media:content url="http://www.sjs-legal.com/media/2009/02/intelence_bottle_lr1.jpg" medium="image">
			<media:title type="html">intelence_bottle_lr1</media:title>
			<media:thumbnail url="http://www.sjs-legal.com/media/2009/02/intelence_bottle_lr1-109x150.jpg" />
		</media:content>
	</item>
		<item>
		<title>HIV medication carries warning of SJS</title>
		<link>http://www.sjs-legal.com/news/2009/01/23/hiv-medication-carries-warning-of-sjs/</link>
		<comments>http://www.sjs-legal.com/news/2009/01/23/hiv-medication-carries-warning-of-sjs/#comments</comments>
		<pubDate>Fri, 23 Jan 2009 14:00:42 +0000</pubDate>
		<dc:creator>Jennifer Walker-Journey</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[adverse reactions]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[darunavir]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[ibuprofen]]></category>
		<category><![CDATA[NSAID]]></category>
		<category><![CDATA[NSAIDS]]></category>
		<category><![CDATA[Preista]]></category>
		<category><![CDATA[rashes]]></category>
		<category><![CDATA[reactions to medication]]></category>
		<category><![CDATA[SJS]]></category>
		<category><![CDATA[St. John's Wort]]></category>
		<category><![CDATA[Stevens Johnson Syndrome]]></category>
		<category><![CDATA[TENS]]></category>
		<category><![CDATA[Tibotec]]></category>
		<category><![CDATA[toxic epidermal necrolysis]]></category>

		<guid isPermaLink="false">http://www.sjs-legal.com/?p=344</guid>
		<description><![CDATA[The FDA recently approved safety labeling revisions for darunavir tablets, also known as Prezista, to warn of adverse reactions including skin rashes and Stevens Johnson Syndrome (SJS), according to MedScape.
Darunavir, manufactured by Tibotec, belongs to a class of anti-HIV drugs called protease inhibitors (PI). It works to prevent cells infected by HIV from producing new virus, [...]<p>SOURCE: <a href="http://www.sjs-legal.com">Stevens Johnson Syndrome</a> &rsaquo; <a href="http://www.sjs-legal.com/news/2009/01/23/hiv-medication-carries-warning-of-sjs/">HIV medication carries warning of SJS</a></p>
]]></description>
			<content:encoded><![CDATA[<p>The <strong>FDA</strong> recently approved safety labeling revisions for <strong>darunavir</strong> tablets, also known as <strong>Prezista</strong>, to warn of <strong>adverse reactions</strong> including skin rashes and <a href="http://www.sjs-legal.com"><strong><a href="http://www.sjs-legal.com/" title="" rel="external">Stevens Johnson Syndrome</a> (SJS)</strong></a><strong>,</strong> according to <a href="http://www.medscape.com/viewarticle/587156">MedScape</a>.<span id="more-344"></span></p>
<p><strong>Darunavir</strong>, manufactured by <strong>Tibotec</strong>, belongs to a class of <strong>anti-HIV</strong> drugs called protease inhibitors (PI). It works to prevent cells infected by <strong>HIV</strong> from producing new virus, thus reducing the amount of virus in the body. <strong>Darunavir</strong> must be coadministered with 100-mg ritonavir and with other antiretroviral agents. It was approved by the <strong>FDA</strong> in June 2006 for <strong>HIV</strong>-positive adults who were treatment-experienced.</p>
<p>Last October, <strong>darunavir</strong> was approved for <strong>HIV</strong>-positive individuals beginning treatment. The medication has proven effective for patients who are not likely to respond to older PIs and for those who are starting antiretroviral therapy for the first time.</p>
<p><strong><a href="http://www.sjs-legal.com/tag/sjs/" class="st_tag internal_tag" rel="tag" title="Posts tagged with SJS">SJS</a></strong> and its more severe form, <a href="http://www.sjs-legal.com"><strong><a href="http://www.sjs-legal.com/toxic-epidermal-necrolysis-syndrome/" title="" rel="external">toxic epidermal necrolysis</a> (TEN),</strong></a> are <strong>serious adverse reactions to medication</strong>. The reaction begins with a rash that blisters over, causing the skin to peel off in sheets. Mucus membranes in the eyes and mouth also can blister over, leading to dehydration, infection, blindness, and even death. More than 200 medications have been linked to <strong><a href="http://www.sjs-legal.com/tag/sjs/" class="st_tag internal_tag" rel="tag" title="Posts tagged with SJS">SJS</a></strong> and <strong>TEN</strong>, including <strong>NSAIDs</strong> such as <strong>ibuprofen</strong>, <strong><a href="http://www.sjs-legal.com/tag/antibiotics/" class="st_tag internal_tag" rel="tag" title="Posts tagged with antibiotics">antibiotics</a></strong> and <strong>anti-seizure</strong> medication.</p>
<p>Other warning included in the labeling revisions for <strong>darunavir</strong> include warnings of potential drug-drug interactions and pregnancy risk. <strong>Darunavir</strong> should not be taken with dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, pimozide, oral midazolam, triazolam, St. John&#8217;s Wort, lovastatin, simvastatin, or rifampin.</p>
<p><strong>Darunavir</strong> also should be taken during pregnancy only if the potential benefit justifies the potential risk, according to the report. Mothers on <strong>darunavir</strong> should not breast feed, and children younger than 3 should not take <strong>darunavir</strong>.</p>
<p>SOURCE: <a href="http://www.sjs-legal.com">Stevens Johnson Syndrome</a> &rsaquo; <a href="http://www.sjs-legal.com/news/2009/01/23/hiv-medication-carries-warning-of-sjs/">HIV medication carries warning of SJS</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.sjs-legal.com/news/2009/01/23/hiv-medication-carries-warning-of-sjs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
	</item>
	</channel>
</rss>
